Myozyme patents invalidated in first biopharma IPR rulings


The US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has handed down what are thought to be the first written decisions in inter partes review proceedings that concern the biopharmaceutical industry.

US Patent Trial and Appeal Board, inter partes review, America Invents Act, Myozyme, patentability, Genzyme